Feared self and responsibility in obsessive compulsive phenomena.

Br J Clin PsycholApr 27, 2026 (epub)
Clinical ResearchPsychiatry

Yoon-Hee Yang, Tess Jaeger, Richard Moulding

✦ AI-curated · Sources linked

In 30 seconds

This online randomized experiment examined whether heightened responsibility and feared-self cues influence obsessive-compulsive tendencies in 185 participants (mean age 28.11 years). Participants received heightened-responsibility or control instructions and completed vignettes priming morality-related feared self, culpability-related feared self, or a neutral scenario. Outcomes included discomfort, response time, and checking behaviour. The responsibility manipulation did not significantly affect outcomes. In contrast, participants’ existing feared-self levels and the feared-self manipulation were associated with significantly greater average discomfort, supporting a role for feared-self processes in discomfort-related responses.

Key findings

  • The responsibility manipulation produced no significant variation in the measured outcomes.
  • Existing feared-self levels and feared-self priming were linked to significantly higher average discomfort.

Why it matters

The experiment suggests that feared-self concerns may contribute to discomfort in obsessive-compulsive phenomena, whereas experimentally heightened responsibility did not alter the measured responses in this study. This distinction may inform cognitive models by highlighting feared-self processes as a potential component of how discomfort-related responses arise.

What to keep in mind

The online experiment assessed obsessive-compulsive tendencies using vignette tasks and behavioural measures; the abstract does not report clinical outcomes or longer-term follow-up.

Source

Published in Br J Clin Psychol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.